AbbVie Inc. ABBV | NYSE
ABBV last paid $1.73 a share on Oct 19, and returned 27.7% over 12 months with dividends counted. · 1-year total return +27.7% · Track ABBV in a free portfolio
Company Overview:
10 Year ABBV Performance Metrics:
ABBV Dividend Charts
Build Custom Charts
ABBV Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
ABBV Dividends Info:
Projected Future Returns & Dividends for ABBV
Based on past 10-year performance, here are ABBV growth metrics:
Share price CAGR of +16.83%
Dividend CAGR of +11.84%
Using ABBV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ABBV (DRIP) | ABBV - No DRIP | |
|---|---|---|
| Current Price | $286.20 | $286.20 |
| Start Shares | 34.94 | 34.94 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 42.66 | 34.94 |
| Dividends Payment | $5.30 | $5.30 |
| Annual Dividends | $904 | $740 |
| Yield on cost | 9.04% | 7.40% |
| Share Price | $1,355.68 | $1,355.68 |
| Total Dividends | $4,765 | $4,210 |
| Final Value | $57,839 | $51,578 |
NOTE: Above numbers are our estimate based on ABBV's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
AbbVie Inc. (ABBV) had its IPO on 2013-01-02, and is traded on NYSE stock exchange.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV website: https://www.abbvie.com
DCF Model — ABBV
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
